Form 4: Sensei Biotherapeutics CEO Granted Stock Options

Sensei Biotherapeutics CEO, John Celebi, was granted stock options for 360,000 shares on February 14, 2025, as reported in a Form 4 filing with the SEC.

Summary

• John Celebi, the President and CEO of Sensei Biotherapeutics, Inc., was granted stock options to purchase 360,000 shares of common stock.
• The transaction occurred on February 14, 2025.
• The exercise price of the stock options is $0.476 per share.
• The options vest over four years, with 25% vesting on February 14, 2026, and the remainder vesting monthly over the subsequent three years, contingent upon continuous service with the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard part of executive compensation.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of four years with a one-year cliff (25% vesting after one year) is also a common practice.

Stakeholder Impact

• The stock option grant aligns the CEO's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, Sensei Biotherapeutics, SNSE, CEO, John Celebi, executive compensation, insider transaction